What's Going On With Seelos Therapeutics Stock Tuesday?
Portfolio Pulse from Dylan Berman
Seelos Therapeutics (NASDAQ:SEEL) shares surged over 72% after signing a material transfer agreement with the U.S. Army to supply intranasal racemic ketamine (SLS-002) for a PTSD clinical trial. The trial, funded by the Department of Defense, will assess the drug's effectiveness and safety for military personnel and veterans.
September 24, 2024 | 6:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seelos Therapeutics' stock rose significantly after announcing a partnership with the U.S. Army for a PTSD clinical trial using SLS-002. This agreement could lead to significant advancements in PTSD treatment, potentially increasing the company's market value.
The partnership with the U.S. Army for a clinical trial is a significant development for Seelos Therapeutics, as it validates the potential of SLS-002 in treating PTSD. The stock's 72% increase reflects investor optimism about the trial's potential success and its impact on the company's future prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100